• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » SARS-CoV-2

Articles Tagged with ''SARS-CoV-2''

Omeros finds narsoplimab benefits COVID-19 patients in small trial

Aug. 10, 2020
By Michael Fitzhugh
Shares of Omeros Corp. (NASDAQ:OMER) jumped 50.9% to $21.32 on Aug. 10 after it reported that six critically ill COVID-19 patients treated with its investigational lectin-pathway inhibitor, narsoplimab, recovered from the disease. The company said it will now seek government support to accelerate the drug’s large-scale manufacture. "We look forward to being able to make narsoplimab broadly available to hospitalized COVID-19 patients," said Omeros CEO Greg Demopulos.
Read More

Other news to note for Aug. 10, 2020

Aug. 10, 2020
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Borqs Technologies, Fujifilm Sonosite, Hoth Therapeutics, Mallinckrodt, Sight Sciences, Spectral Medical, Sysmex America, Siemens Healthineers, Thermo Fisher Scientific.
Read More

Other news to note for Aug. 10, 2020

Aug. 10, 2020
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Boehringer Ingelheim, BMS, Dragonfly, Gigagen, Ibio, Isotherapeutics, Janssen, Lilly, Pieris, Monopar, Northstar, Novocellbio, Onko, Pharmamar, Secura, Verastem.
Read More

In the clinic for Aug. 10, 2020

Aug. 10, 2020
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Anaptysbio, Avadel, Axsome, BMS, Eli Lilly, Enlivex, Genentech, Humanigen, Innovent, Kamada, Krystal, Logicbio, Ovid, Pharming, Precigen, Rhovac, Seres.
Read More
Coronavirus vs U.S. wrecking balls

Harvard’s Mina says ‘archaic view’ of testing impeding cheap surveillance testing for COVID-19

Aug. 7, 2020
By Mark McCarty
The COVID-19 pandemic has sparked some innovation in testing, but not all that innovation has made it to market. Michael Mina, an assistant professor of epidemiology at the Chan School of Public Health at Harvard University, said on an Aug. 7 conference call that the U.S. FDA’s “archaic view” of testing is impeding the use of paper strip tests he said would turn the tide in the effort to contain the pandemic.
Read More

Regulatory front for Aug. 7, 2020

Aug. 7, 2020
The latest global regulatory news, changes and updates affecting medical devices and technologies, including: MITA.
Read More

Regulatory actions for Aug. 7, 2020

Aug. 7, 2020
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Co-Diagnostics, Guardant Health, Scientia Vascular.
Read More
Coronavirus cash

Pandemic developers account for 40% of 2020’s record financings

Aug. 7, 2020
By Karen Carey
Out of 922 biopharma financings so far in 2020, nearly a quarter of them – 211 – were done by companies working on a COVID-19 therapeutic or vaccine. More strikingly, however, the $27.8 billion raised by those pandemic-focused firms represents about 40% of the $71.8 billion total collected through the end of July. That amount is the highest BioWorld has ever tracked.
Read More

Regulatory actions for Aug. 6, 2020

Aug. 6, 2020
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Adaptive Biotechnologies, Cardiacsense, Joimax, Scientia Vascula, Surmodics, Vela Diagnostics.
Read More

Other news to note for Aug. 6, 2020

Aug. 6, 2020
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aethlon Medical, Avacta Group, BBI Solutions, Bio-Techne, Btl Industries, Cerner, Cytiva, GW Plastics, Helius Medical Technologies, Hologic, Lrvhealth, Nanostring Technologies, Nanotronics, Nolato, Ortho Regenerative Technologies, Radnet, T2 Biosystems, Xealth, Xenex Disinfection Services.
Read More
Previous 1 2 … 98 99 100 101 102 103 104 105 106 … 134 135 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 10, 2025.
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 8, 2025
  • 3D rendering of a molecular glue mediating the interaction between two proteins

    With surface mimicry, molecular glues shed hairpin need

    BioWorld Science
    Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe